A recurring design pattern in politicized medicine is running long, universally‑offer trials that deliberately delay definitive answers and ensure eventual universal access to the intervention. Such trials can function to postpone accountability, re‑entrench contested treatments, and recreate—at high cost—data that already exist but were never analyzed.
— If trials become a way to defer scrutiny rather than to resolve uncertainty, regulators, funders, and courts need rules (data linkage mandates, fast‑track analyses, prespecified stopping criteria) to prevent research from becoming policy theater.
Kristen French
2026.09.17
78% relevant
The article documents how the conspicuous subjective effects of psychedelics let participants and therapists 'know' treatment assignment, turning trials into performative events that can inflate efficacy—precisely the phenomenon captured by the 'clinical trials as theater' idea; it cites a JAMA Psychiatry proposal from UCSF/UCSD/Stanford to mask that theatrical signal with active placebos and partial disclosure.
Tyler Cowen
2026.09.05
90% relevant
The post links to a New York Times piece about clinical trials as the main obstacle; that directly connects to the existing claim that clinical‑trial design and incentives are a central bottleneck for medical progress and policy, implicating actors such as trial sponsors, regulators, and journals.
Jake Currie
2026.04.29
70% relevant
This Nature Medicine study is an instance of a clinical trial producing high‑visibility, practice‑changing claims about a new intervention (extracorporeal antibody filtration for sFlt‑1) that will shape public discussion and policy around pregnancy care and emergency delivery avoidance.
Andy Lewis
2025.11.29
100% relevant
NHS PATHWAYS trial: 226 children randomized, everyone eventually offered blockers, existing Tavistock referral data not linked or re‑analysed, Cass review finding weak evidence.